528MO Is re-introduction or continuation of PARP inhibitors after local therapy for oligo-metastatic progression in patients with relapsed ovarian cancer relevant?
| Autor: | Thibault, G., Kfoury, M., Lorusso, D., Floquet, A., Ventriglia, J., Salaun, H., Moubarak, M., Rivoirard, R., Polastro, L., Favier, L., You, B., Berton-Rigaud, D., De La Motte Rouge, T., Mansi, L., Abdeddaim, C., Prulhiere, K., Lancry Lecomte, L., Provansal Gross, M., Dalban, C., Ray-Coquard, I.L. |
|---|---|
| Zdroj: | In Annals of Oncology September 2022 33 Supplement 7:S787-S788 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|